2019

Abdominal aortic calcification, bone mineral density and fractures: a systematic review and meta-analysis protocol

Alexander J. Rodríguez

Kevin Leow

Pawel Szulc

David Scott

Peter Ebeling

See next page for additional authors
Abdominal aortic calcification, bone mineral density and fractures: a systematic review and meta-analysis protocol

Alexander J Rodríguez,1 Kevin Leow,2 Pawel Szulc,3 David Scott,¹ Peter Ebeling,¹ Marc Sim,⁶,⁵ Germaine Wong,² Wai H Lim,⁶,⁷ John T Schousboe,⁸ Douglas P Kiel,⁹ Richard L Prince,⁷,¹⁰ Joshua R Lewis²,⁴,⁵

ABSTRACT

Introduction Abdominal aortic calcification (AAC) is associated with low bone mass and increased fracture risk. Two previous meta-analyses have investigated the association between AAC and fracture. However, these meta-analyses only identified articles until December 2016, undertook limited searches and did not explore potential sources of between-study heterogeneity. We aim to undertake a sensitive and comprehensive assessment of the relationship between AAC, bone mineral density (BMD) as well as prevalent and incident fractures.

Methods We will search MEDLINE, EMBASE, Web of Science core collection and Google Scholar (top 200 articles sorted by relevance) from their inception to 1 June 2018. Reference lists of included studies and previous systematic reviews will be hand searched for additional eligible studies. Retrospective and prospective cohort studies (cross-sectional, case–control and longitudinal) reporting the association between AAC, BMD and fracture at any site will be included. At least two investigators will independently: (A) evaluate study eligibility and extract data, with a third investigator to adjudicate when discrepancies occur, (B) assess study quality by the Newcastle-Ottawa Scale for each cohort/study. The meta-analysis will be reported in adherence to the Meta-analysis of Observational Studies in Epidemiology criteria. AAC will be grouped as either: (1) AAC present or absent, (2) AAC categorised as ‘low’ (referent—lowest reported group) versus ‘high’ (all other groups) or (3) dose–response when AAC was assessed in ≥3 groups. Where primary event data were reported in individual studies, pooled risk differences and risk ratios with 95% CI will be calculated, from which, a summary estimate will be determined using DerSimonian-Laird random effects models. For the AAC and BMD pooled analyses, estimates will be expressed as standardised mean difference with 95% CI. We will examine the likelihood of publication bias and where possible, investigate potential reasons for between-study heterogeneity using subgroup analyses and meta-regression.

Ethics and dissemination The study will be submitted to a peer-reviewed journal and disseminated via research presentations.

PROSPERO registration number CRD42018088019.

INTRODUCTION

Vascular and bone diseases are both chronic age-related diseases that share many common dietary and lifestyle risk factors and cause considerable morbidity and mortality.¹ Atherosclerotic lesions in the abdominal aorta generally begin around the major vessel bifurcations and branching arteries such as the inferior mesenteric artery and the lumbar arteries that supply blood and nutrients to the lumbar vertebrae.² Occlusion of these vessels may cause ischaemia in the lumbar spine and may result in disc degeneration and asymmetric vertebral fractures.³ Additionally, the underlying processes regulating arterial calcification share many similarities to bone physiology⁴ and calcified atherosclerotic plaques release both local and systemic osteochondrogenic factors that may affect regional and systemic bone homoeostasis.⁵ Conversely circulating levels of factors regulating bone homoeostasis may also regulate vascular
califications with a number of studies demonstrating osteoporosis and bone mineral density (BMD) being a risk factor for cardiovascular disease (CVD). Assessment of lateral spine images is often undertaken to detect prevalent vertebral fractures and has been shown to improve fracture prediction. These images can also be used to assess the degree of abdominal aortic calcification (AAC). To date, there are conflicting findings as to whether AAC is associated with BMD and fractures and whether or not these associations are due to ageing, shared fracture risk factors or are a non-traditional independent fracture risk factor. Recent meta-analyses published in 2016 and 2017 looking at observational studies, showed that people with any or high AAC were at greater risk of fractures than those with no or low AAC. However, the previous studies by Chen and Yu only identified a limited number of articles due to the search strategies employed (searches found 91 and 105 articles, respectively) and the meta-analyses missed many of the known studies in the area (by way of example—both studies missed Wang et al). For example, our recent search identified 1561 potentially eligible reports. Furthermore, both meta-analyses identified unexplained moderate-high heterogeneity that needs to be explored further. As such uncertainty exists as to the importance of identifying AAC for incident fracture risk, particularly with respect to AAC cut-points, types of fracture and potential explanations for the observed between-study heterogeneity. We will, therefore, undertake a meta-analysis of studies reporting on AAC, BMD at any site and prevalent and incident fractures at any site.

OBJECTIVES
1. To determine the association between AAC with BMD at any site.
2. To determine the association between AAC with prevalent fractures (cross-sectional) by reported prevalent fracture sites.
3. To determine the association between AAC with incident fractures by reported incident fracture sites.
4. To assess the impact of potential effect modifiers, including aspects of clinical, methodological and statistical heterogeneity on previous published findings.

METHODS AND ANALYSIS
The systematic review and meta-analysis reported in adherence to the Meta-analysis of Observational Studies in Epidemiology reporting criteria. Patient and public involvement statement There is no patient or public involved in this systematic review/meta-analysis.

Eligibility criteria for studies included in this review
Criteria for considering studies for review
a. Observational studies in humans. These include cohort (both retrospective and prospective cohort studies), case–control and cross-sectional studies that report eligible exposure(s) and outcome(s).
b. AAC assessed by any methodology.
c. Report any BMD measure or prevalent or incident fracture outcome.

Exclusion criteria
a. Reviews of existing literature.

Exposure
AAC identified from either radiography, dual X-ray absorptiometry (DXA) machine or CT. AAC will be presented as:
a. AAC present or absent.
b. AAC categorised as low (referent—lowest reported group) versus moderate to high (all other reported groups combined).
c. AAC dose–response when AAC was assessed in three or more groups categorised as low (lowest reported category), moderate (middle reported category[ies]) and high (highest reported category).

Outcomes
1. BMD (by site).
2. Prevalent fractures (by fracture site).
3. Incident fractures (by fracture site).

Cohort characteristics for meta-regression (where available)
- Cohort age (cohort mean).
- Gender (% female).
- Years since menopause (cohort mean).
- Chronic kidney disease (% of cohort).
- Diabetes (% of cohort).
- History of smoking (% of cohort).
- History of fracture (% of cohort).
- Location of study (Europe, Asia-Pacific, North America), that is, are association consistent across ethnicities and nation wealth.
- Prevalence of CVD medication use (% of cohort).
- History of CVD (% of cohort).

Search strategies
A comprehensive literature search within MEDLINE, Web of Science core collection and EMBASE databases will be conducted to source all possibly relevant studies for review, without language restriction. Google Scholar will be searched for the top 200 articles sorted by relevance. The search terms will be combined with the boolean ‘AND’ to find all potentially relevant studies. Conference proceedings and abstracts will also be evaluated. A hand
search of reference lists of eligible studies and previous meta-analyses will also be undertaken. Non-English papers will be translated and evaluated for eligibility. If more than one publication of a study is retrieved, articles with the most up to date and complete information will be included, although additional unique data from all sources will be considered and included when relevant. Examples of the search strategy are shown in table 1.

### Process for selecting studies
Two or more independent authors (AR, KL, MS and JRL) will assess retrieved citations to assess studies for eligibility. Briefly, the process for selecting studies for inclusion in the review and meta-analysis will be as follows: merge all identified records using EndNote; remove duplicate records of the same report; retrieve full text of the potentially relevant reports; link together multiple reports of the same study (using the first or largest report as the primary record and subsequent reports to supplement other data); examine full-text reports for compliance with eligibility criteria; correspond with investigators, where appropriate, to clarify study eligibility and request missing data; make final decisions on study inclusion. Discrepancies about inclusion will be resolved via iteration and consensus or a third reviewer if consensus cannot be reached between the two reviewers. Excluded studies identified that may plausibly be expected to be an included will be reported in online supplementary data with a detailed explanation for the reason of exclusion.

### Risk of bias and quality assessment
The risk of bias for observational studies will be assessed using the Newcastle-Ottawa Scale (NOS). An example of this scale is provided in online supplementary material 1A–D. In addition, publication bias will be assessed by visual inspection of a funnel plots and the Egger’s and Begg’s regression tests. Summary estimates of the confidence placed on the evidence will be evaluated using the Grading of Recommendations Assessment Development and Evaluation (GRADE) of evidence about prognosis. GRADE for evidence about prognosis starts with high-quality evidence that can then be rated down. These criteria are based on; (1) five domains diminishing confidence (−1 for risk of bias, inconsistency, imprecision, indirectness and publication bias) and (2) two situations increasing confidence (+1 or +2 for large-very large effect size and a +1 for a dose–response gradient (increasing pooled relative risks for fractures with increasing severity of AAC)).

### Statistical analysis and data synthesis
Analysis of outcome variables will be presented according to either: (1) AAC present or absent (2) AAC categorised as ‘low’ (refferent—lowest reported group) versus ‘high’ (all other groups) or (3) dose–response when AAC was assessed in three or more groups. For the dose–response analysis, the lowest reported group (low AAC group) will be compared with the middle group(s) versus the highest reported AAC group (high AAC). Where data on more than three groups of AAC were presented the middle groups were combined as ‘moderate AAC’. This approach was selected due to many studies reporting on variable number of AAC groups with the majority of studies using different cut-points for these groupings. Data on the severity of AAC quantification presented as a continuous measure or in three or more groupings of AAC will be used to determine the impact of increased abdominal aortic calcium load on outcomes. Where primary event data were reported in individual studies, pooled risk differences and risk ratios with 95% CIs will be calculated, from which, a summary estimate was determined using

### Table 1 Example search strategies

<table>
<thead>
<tr>
<th>Keyword</th>
<th>MEDLINE</th>
<th>Embase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population=adults</td>
<td>No search strategy</td>
<td>No search strategy</td>
</tr>
<tr>
<td>Intervention/Test=aortic calcification</td>
<td>exp Vascular Calcification/or exp Calcinosis/or exp Vascular Diseases/or arterial calcification. or exp Arteriosclerosis/or exp Arterial Occlusive Diseases/or exp Aortic Diseases/ or aortic.mp or vascular calcifications.mp. or calcification.mp or calcified atherosclerotic plaque.mp or arterial calcification.mp or aorta calcification.mp or aorta calcification.mp and aort$.mp and calc$.mp vascular calcification.mp. or exp blood vessel calcification/or artery calcification.mp. or exp artery calcification/or exp coronary artery disease/or exp artherosclerosis/or calcified atherosclerosis.mp or arterial calcium. mp or calcified atherosclerotic plaque.mp or calcification.mp or calcified atherosclerotic plaque.mp or arteriosclerosis.mp or calcification.mp or vascular calcification.mp or vascular calcifications.mp or arteriosclerosis.mp or aortcalcification.mp or calcifications.mp or arteriosclerosis.mp or extracoronary.mp and aort$.mp and calc$.mp</td>
<td></td>
</tr>
<tr>
<td>Methodology=observational</td>
<td>No search strategy</td>
<td>No search strategy</td>
</tr>
<tr>
<td>Comparator=None</td>
<td>No search strategy</td>
<td>No search strategy</td>
</tr>
<tr>
<td>Outcome</td>
<td>bone mineral density.mp or exp Bone Density/ or Fracture.mp or Fractures.mp</td>
<td>bone mineral density.mp or exp bone density/ or fracture.mp or fractures.mp or exp fracture/</td>
</tr>
<tr>
<td>Additional specific filters</td>
<td>Human</td>
<td>Human</td>
</tr>
</tbody>
</table>

The reference lists of recent literature reviews and guidelines will be hand searched for possibly relevant studies.
DerSimonian-Laird random effects models. For the AAC and BMD pooled analyses, estimates will be expressed as standardised mean difference with 95% CI. Values will be considered significant if the 95% CI of the point estimate does not cross unity. Between-study heterogeneity will also be investigated by using subgroup analyses and the I^2 statistic by study ID which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta-analysis. 17 18 We will evaluate for heterogeneity using the I^2 statistic and considered the I^2 thresholds of <25%, 25%–49%, 50%–75% and >75% to represent low, moderate, high and very-high heterogeneity.

**Subgroup analysis and investigation of heterogeneity**
We will perform meta-regression of cohort characteristics to identify factors potentially explaining heterogeneity as well as performing subgroup analyses. P<0.01 will be considered statistically significant for subgroup analyses. Preplanned subgroup analyses to explore statistical heterogeneity will include stratification by:
1. Subgroups based on clinical heterogeneity, for example, disease populations (general population, diabetics, chronic kidney disease, other) and age groups (<60 years, 60–69 years and ≥70 years).
2. Methodological heterogeneity, for example, AAC assessment methods (radiography, DXA or CT), thresholds to define high or severe AAC, fracture reporting and validation.
3. Statistical heterogeneity, for example, cohort characteristics (mean ages of the cohorts).

**Further analyses**
Where data on the severity of AAC quantification are presented as a continuous measure or in tertile/category these data will be used to determine the impact of increased abdominal aortic calcium load on prognosis. Where AAC is not scored using the AAC24 scale equivalent values will be relative to estimated vertebral heights from similar aged populations. Where AAC is assessed by CT the categorical low vs moderate and high AAC will be used.

**Sensitivity analysis**
We will carry out sensitivity analyses for:
1. Large studies alone to establish how much they dominate the results (n>500 participants).
2. Methodology—we will assess the methodological quality of studies using the NOS for assessing the quality of non-randomised studies in meta-analyses (online supplementary material 1). For the purpose of this sensitivity analysis, we will use three categories of quality (good, fair or poor).
3. Studies conducted in individuals without a history of a prior fracture (as this is the biggest risk factor for a new fracture).
4. Studies conducted in high-income versus low-income countries.
5. Studies that included non-osteoporotic fractures (fractures of the toes, fingers, face and skull fractures).
6. Study design bias comparing outcomes in cross-sectional and prospective studies (given that prospective studies may also include prevalent fractures and BMD measurements at baseline that can be analysed cross-sectionally).

**CONCLUDING STATEMENT**
Previous meta-analyses on this topic have a number of important limitations. By undertaking the preplanned comprehensive review and meta-analysis, we will gain better understanding of the relationship between AAC, BMD and increased fracture risk. The review will provide impetus for further research, diagnosis and treatment of this novel fracture risk factor. This review will also evaluate the quality of the published evidence and our confidence in the estimates for the meta-analysis, while identifying important knowledge gaps, potential sources of between-study heterogeneity and issues with imaging, assessing or reporting of AAC in published studies.

**Ethics and dissemination**
The study will be submitted to a peer-reviewed journal and disseminated via research presentations.

**Author affiliations**
1Bone and Muscle Health Research Group, School of Clinical Sciences at Monash Health, Monash Medical Centre, Victoria, Australia.
2The University of Sydney, Centre for Kidney Research, School of Public Health, Sydney Medical School, Children’s Hospital at Westmead, New South Wales, Australia.
3INSERM UMR 1033, University of Lyon, Hospices Civils de Lyon, Lyon, France.
4School of Medical and Health Sciences, Edith Cowan University, Western Australia, Australia.
5Medical School, Royal Perth Hospital Unit, The University of Western Australia, Western Australia, Australia.
6Department of Renal Medicine, Sir Charles Gairdner Hospital, Western Australia, Australia.
7Medical School, The University of Western Australia, Western Australia, Australia.
8Division of Health Policy and Management, Park Nicollet Osteoporosis Center and Health Partners Institute, University of Minnesota, Minneapolis, USA.
9Hinda and Arthur Marcus Institute for Aging Research, Hebrew Senior Life, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
10Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Perth, Australia.

**Contributors** AR, KL, PS, DS, PE, MS, GW, WHL, JTS, DPX, RLP and JRL contributed to the study concept and design. AR and KL led the writing of the manuscript and is the primary designer of the protocol under the guidance of JRL. JTS and PS and all authors conceived the conceptual ideas presented in the revised protocol critically. All authors read and approved the revised version and final supported versions. JRL has the primary responsibility for the final content.

**Funding** The salaries of JRL and DS are supported by a National Health and Medical Research Council of Australia (NHMRC) Career Development Fellowship (ID: 1107474 and 1123014, respectively).

**Disclaimer** Funding agencies had no input into any aspect of the design and management of this study.

**Competing interests** None declared.

**Patient consent for publication** Not required.
REFERENCES